Press release
Pyelonephritis Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Pyelonephritis Clinical Trials
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pyelonephritis pipeline constitutes 20+ key companies continuously working towards developing 20+ Pyelonephritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Pyelonephritis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pyelonephritis Market.
The Pyelonephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Pyelonephritis Pipeline Analysis [https://www.delveinsight.com/report-store/pyelonephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some of the key takeaways from the Pyelonephritis Pipeline Report:
* Pyelonephritis Companies across the globe are diligently working toward developing novel Pyelonephritis treatment therapies with a considerable amount of success over the years.
* Pyelonephritis companies working in the treatment market are Wockhardt, Sinovent, Entasis Therapeutics, Melinta Therapeutics, Allecra Therapeutics GmbH, Entasis Therapeutics Holdings Inc, Iterum Therapeutics Plc, Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd, Merck & Co Inc, MerLion Pharmaceuticals Pte Ltd, Nabriva Therapeutics Plc, Paratek Pharmaceuticals Inc, Pfizer Inc, Qilu Pharmaceutical Co Ltd, VenatoRx Pharmaceuticals Inc, XuanZhu Biological Technology Co Ltd and others, are developing therapies for the Pyelonephritis treatment.
* Emerging Pyelonephritis therapies such as WCK-5222, XNW 4107, ETX2514SUL and others are expected to have a significant impact on the Pyelonephritis market in the coming years.
* On December 2023, Wockhardt announced results of a Phase 3, Randomized, Double-blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults.
* On June 2023, Meiji Seika Pharma Co., Ltd announced results of a Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults.
Pyelonephritis Overview
Pyelonephritis is a bacterial infection of the kidneys, typically stemming from a urinary tract infection (UTI) that ascends to the kidneys. It commonly affects women and can occur suddenly (acute pyelonephritis) or develop gradually (chronic pyelonephritis). The most common causative agent is Escherichia coli, though other bacteria can also be responsible.
Symptoms of pyelonephritis may include fever, chills, flank pain (pain in the side or back), nausea, vomiting, and frequent urination. In severe cases, individuals may experience confusion or symptoms of sepsis, a life-threatening condition characterized by systemic inflammation in response to infection.
Pyelonephritis Diagnosis typically involves a physical examination, urinalysis, urine culture, and imaging studies such as ultrasound, CT scan, or MRI to assess kidney involvement and rule out complications like abscess formation or kidney stones.
Pyelonephritis Treatment often involves antibiotics to eradicate the bacterial infection. In severe cases or those involving complications, hospitalization may be necessary for intravenous antibiotic therapy and supportive care. Adequate hydration is important to help flush out bacteria from the urinary tract. Patients may also require pain management and medications to alleviate fever and discomfort.
Untreated or recurrent pyelonephritis can lead to complications such as kidney damage, abscess formation, sepsis, or even kidney failure, emphasizing the importance of prompt diagnosis and treatment. Additionally, preventive measures such as good hygiene, proper hydration, and prompt treatment of UTIs can help reduce the risk of developing pyelonephritis.
Get a Free Sample PDF Report to know more about Pyelonephritis Pipeline Therapeutic Assessment- Pyelonephritis Treatment Market [https://www.delveinsight.com/sample-request/pyelonephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Pyelonephritis Route of Administration
Pyelonephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Pyelonephritis Molecule Type
Pyelonephritis Products have been categorized under various Molecule types, such as
* Oligonucleotide
* Peptide
* Small molecule
Pyelonephritis Pipeline Therapeutics Assessment
* Pyelonephritis Assessment by Product Type
* Pyelonephritis By Stage and Product Type
* Pyelonephritis Assessment by Route of Administration
* Pyelonephritis By Stage and Route of Administration
* Pyelonephritis Assessment by Molecule Type
* Pyelonephritis by Stage and Molecule Type
DelveInsight's Pyelonephritis Pipeline Report covers around 20+ products under different phases of clinical development like-
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration
Further Pyelonephritis product details are provided in the report. Download the Pyelonephritis pipeline report to learn more about the emerging Pyelonephritis therapies- Pyelonephritis Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/pyelonephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Pyelonephritis Pipeline Analysis:
The Pyelonephritis pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Pyelonephritis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pyelonephritis Treatment.
* Pyelonephritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Pyelonephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pyelonephritis market.
Download Sample PDF Report to know more about Pyelonephritis drugs and therapies- Pyelonephritis Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/pyelonephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of Pyelonephritis Pipeline Drug Insight
* Coverage: Global
* Key Pyelonephritis Companies: Wockhardt, Sinovent, Entasis Therapeutics, Melinta Therapeutics, Allecra Therapeutics GmbH, Entasis Therapeutics Holdings Inc, Iterum Therapeutics Plc, Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd, Merck & Co Inc, MerLion Pharmaceuticals Pte Ltd, Nabriva Therapeutics Plc, Paratek Pharmaceuticals Inc, Pfizer Inc, Qilu Pharmaceutical Co Ltd, VenatoRx Pharmaceuticals Inc, XuanZhu Biological Technology Co Ltd and others.
* Key Pyelonephritis Therapies: WCK-5222, XNW 4107, ETX2514SUL and others.
* Pyelonephritis Therapeutic Assessment: Pyelonephritis current marketed and Pyelonephritis emerging therapies
* Pyelonephritis Market Dynamics: Pyelonephritis market drivers and Pyelonephritis market barriers
Request for Sample PDF Report for Pyelonephritis Pipeline Assessment and clinical trials - Pyelonephritis Therapeutics Market [https://www.delveinsight.com/sample-request/pyelonephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Pyelonephritis Report Introduction
2. Pyelonephritis Executive Summary
3. Pyelonephritis Overview
4. Pyelonephritis- Analytical Perspective In-depth Commercial Assessment
5. Pyelonephritis Pipeline Therapeutics
6. Pyelonephritis Late Stage Products (Phase II/III)
7. Pyelonephritis Mid Stage Products (Phase II)
8. Pyelonephritis Early Stage Products (Phase I)
9. Pyelonephritis Preclinical Stage Products
10. Pyelonephritis Therapeutics Assessment
11. Pyelonephritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pyelonephritis Companies
14. Pyelonephritis Key Products
15. Pyelonephritis Unmet Needs
16 . Pyelonephritis Market Drivers and Barriers
17. Pyelonephritis Future Perspectives and Conclusion
18. Pyelonephritis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pyelonephritis-clinical-trials-analysis-2024-fda-approvals-therapies-mechanism-of-action-route-of-administration-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pyelonephritis Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 3561886 • Views: …
More Releases from ABNewswire
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by…
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Pyelonephritis
Pyelonephritis Drug Market: Emerging Trends and Growth Forecast to 2033
The Pyelonephritis Drug Market is expected to reach approximately USD 2.36 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2033.
Pyelonephritis Drug Market Overview
The Pyelonephritis Drug Market is witnessing steady growth due to the rising prevalence of urinary tract infections and the growing need for effective treatment options to prevent kidney-related complications. Increasing antibiotic resistance has heightened demand for advanced therapies and novel…
Pyelonephritis Drug Market Size, Share, Growth, Trends, Analysis and Forecast - …
The global pyelonephritis drug market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). A kidney infection, commonly known as pyelonephritis, is a form of urinary tract infection characterized by inflammation of one or both kidneys. Bacteria or a virus causes the illness, which usually starts in the urinary bladder and spreads to one or both kidneys. Confusion and back pain, chills and high fever, nausea…
Healing the Kidneys: Global Pyelonephritis Drug Market 2024-2031
𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧:
Pyelonephritis, a severe type of urinary tract infection (UTI) affecting the kidneys, can lead to complications if left untreated. The global market for pyelonephritis drugs plays a critical role in addressing this medical condition, offering treatment options to alleviate symptoms and prevent recurrent infections. As we delve into the dynamics of this market, examining its size, share, and the impact of COVID-19, we uncover a landscape shaped by innovation and…
Pyelonephritis Market - Pipeline Review, H2 2022
HTF Market Intelligence released a new research report of 134 pages on title 'Pyelonephritis - Pipeline Review, H2 2022' with detailed analysis, forecast and strategies. The market Study is segmented by key a region that is accelerating the marketization. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources. This section also provides the scope of different…
Pyelonephritis Treatment Market Size Estimated to Observe Significant Growth by …
A kidney infection, also known as pyelonephritis, is a type of urinary tract infection, wherein one or both kidneys are infected. The infection is caused by bacteria or a virus that commonly begins to infect urinary bladder and moves up to one or both the kidneys. Signs or symptoms of pyelonephritis can vary depending on age and could include confusion & back pain, chills & high fever, nausea & vomiting,…
Pyelonephritis-Pipeline Review H2 2018
The Pyelonephritis Market which explains the future and present measurements of the market as for the patterns in play. The principle reason for the investigation is to legitimize the occurrences in the market by giving reader helpful and suitable bits of knowledge on the particulars of the market for the future extent of development and accessible prospects at the current situation with the market. The statistical surveying production additionally manages…
